WO2024254562A3 - Modified immunoglobulin variable heavy domains having reduced immunogenicity - Google Patents

Modified immunoglobulin variable heavy domains having reduced immunogenicity Download PDF

Info

Publication number
WO2024254562A3
WO2024254562A3 PCT/US2024/033155 US2024033155W WO2024254562A3 WO 2024254562 A3 WO2024254562 A3 WO 2024254562A3 US 2024033155 W US2024033155 W US 2024033155W WO 2024254562 A3 WO2024254562 A3 WO 2024254562A3
Authority
WO
WIPO (PCT)
Prior art keywords
variable heavy
immunoglobulin variable
reduced immunogenicity
modified immunoglobulin
heavy domains
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2024/033155
Other languages
French (fr)
Other versions
WO2024254562A2 (en
Inventor
Patrick L. LUPARDUS
Deepti ROKKAM
Michael TOTAGRANDE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synthekine Inc
Original Assignee
Synthekine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthekine Inc filed Critical Synthekine Inc
Priority to JP2025571136A priority Critical patent/JP2026521433A/en
Priority to CN202480051018.6A priority patent/CN121941708A/en
Priority to KR1020267000338A priority patent/KR20260021032A/en
Priority to EP24820201.2A priority patent/EP4724499A2/en
Priority to IL324785A priority patent/IL324785A/en
Priority to AU2024285577A priority patent/AU2024285577A1/en
Publication of WO2024254562A2 publication Critical patent/WO2024254562A2/en
Publication of WO2024254562A3 publication Critical patent/WO2024254562A3/en
Priority to MX2025014711A priority patent/MX2025014711A/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present disclosure generally relates to single domain antibodies (sdAbs), such as VH, VHH, and scFv polypeptide fragments, comprising C-terminal modifications that have reduced or eliminated binding to endogenous pre-existing antibodies, isolated polypeptides comprising such modifications, nucleotides encoding such polypeptides, and methods of using such antibody polypeptides.
PCT/US2024/033155 2023-06-07 2024-06-07 Modified immunoglobulin variable heavy domains having reduced immunogenicity Ceased WO2024254562A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2025571136A JP2026521433A (en) 2023-06-07 2024-06-07 Modified immunoglobulin variable weight domains with reduced immunogenicity
CN202480051018.6A CN121941708A (en) 2023-06-07 2024-06-07 Modified immunoglobulin variable heavy domains with reduced immunogenicity
KR1020267000338A KR20260021032A (en) 2023-06-07 2024-06-07 Modified immunoglobulin variable heavy chain domain with reduced immunogenicity
EP24820201.2A EP4724499A2 (en) 2023-06-07 2024-06-07 Modified immunoglobulin variable heavy domains having reduced immunogenicity
IL324785A IL324785A (en) 2023-06-07 2024-06-07 Heavy regions are altered immunoglobulins with reduced immunogenicity
AU2024285577A AU2024285577A1 (en) 2023-06-07 2024-06-07 Modified immunoglobulin variable heavy domains having reduced immunogenicity
MX2025014711A MX2025014711A (en) 2023-06-07 2025-12-05 HEAVY DOMAINS OF MODIFIED IMMUNOGLOBULIN VARIABLES THAT HAVE REDUCED IMMUNOGENICITY

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363506797P 2023-06-07 2023-06-07
US63/506,797 2023-06-07

Publications (2)

Publication Number Publication Date
WO2024254562A2 WO2024254562A2 (en) 2024-12-12
WO2024254562A3 true WO2024254562A3 (en) 2025-03-20

Family

ID=93796476

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/033155 Ceased WO2024254562A2 (en) 2023-06-07 2024-06-07 Modified immunoglobulin variable heavy domains having reduced immunogenicity

Country Status (8)

Country Link
EP (1) EP4724499A2 (en)
JP (1) JP2026521433A (en)
KR (1) KR20260021032A (en)
CN (1) CN121941708A (en)
AU (1) AU2024285577A1 (en)
IL (1) IL324785A (en)
MX (1) MX2025014711A (en)
WO (1) WO2024254562A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017172981A2 (en) * 2016-03-29 2017-10-05 University Of Southern California Chimeric antigen receptors targeting cancer
WO2022040586A2 (en) * 2020-08-21 2022-02-24 Novartis Ag Compositions and methods for in vivo generation of car expressing cells
WO2022061256A2 (en) * 2020-09-21 2022-03-24 Systimmune, Inc. Egfr binding complex and method of making and using thereof
CN115703829A (en) * 2021-08-16 2023-02-17 厦门大学 Single domain antibodies against SARS-CoV-2 and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017172981A2 (en) * 2016-03-29 2017-10-05 University Of Southern California Chimeric antigen receptors targeting cancer
WO2022040586A2 (en) * 2020-08-21 2022-02-24 Novartis Ag Compositions and methods for in vivo generation of car expressing cells
WO2022061256A2 (en) * 2020-09-21 2022-03-24 Systimmune, Inc. Egfr binding complex and method of making and using thereof
CN115703829A (en) * 2021-08-16 2023-02-17 厦门大学 Single domain antibodies against SARS-CoV-2 and uses thereof

Also Published As

Publication number Publication date
WO2024254562A2 (en) 2024-12-12
IL324785A (en) 2026-01-01
JP2026521433A (en) 2026-06-30
KR20260021032A (en) 2026-02-12
CN121941708A (en) 2026-04-28
MX2025014711A (en) 2026-06-01
AU2024285577A1 (en) 2025-12-04
EP4724499A2 (en) 2026-04-15

Similar Documents

Publication Publication Date Title
IL305912A (en) Improved serum albumin binders
RU2019120720A (en) IMPROVED SEPARATE VARIABLE IMMUNOGLOBULIN DOMAINS BINDING WITH SERUM ALBUMIN
PH12021500051A1 (en) Cd3 antigen binding fragments and compositions comprising same
WO2018134235A8 (en) Improved serum albumin binders
RU2018142544A (en) SPECIFIC BINDING PROTEINS AND WAYS OF THEIR APPLICATION
WO2005056600B1 (en) Monoclonal antibodies that bind or neutralize dengue virus
CA3242520A1 (en) Tetrahedral antibodies
WO2023060137A3 (en) Methods and compositions comprising b7-h3 binding polypeptides
ZA202404271B (en) Bispecific cd16a binders
MX2025013732A (en) Modified single-domain antibodies
MX2022012021A (en) Autonomous knob domain peptides.
CN111448214A (en) Miniaturized antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR), polymers thereof, and uses thereof
JP2021529524A5 (en)
JP2024527020A5 (en)
FI4031569T3 (en) STEM CELL FACTOR ANTIBODIES AND METHODS OF USING THEM
WO2023193732A1 (en) Anti-ccr8 antibody or antigen-binding fragment thereof
WO2024151737A3 (en) Cd19-specific antibody constructs and compositions thereof
Li et al. Selection by phage display of nanobodies directed against hypoxia inducible factor‐1α (HIF‐1α)
WO2024102935A3 (en) Antigen-binding domains and methods of use thereof
WO2024148232A3 (en) Anti-il18 binding protein antibodies and methods of use thereof
WO2024220498A3 (en) Antigen-binding domains and methods of use thereof
MX2024006969A (en) Dlk1 antibodies and methods of treating cancer.
JP2024532970A5 (en)
MX2025013491A (en) Methods and compositions for reducing antibody viscosity
WO2020168298A3 (en) Lym-1 and lym-2 antibody compositions and improved car constructs

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24820201

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: AU2024285577

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 202517120829

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2024285577

Country of ref document: AU

Date of ref document: 20240607

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2025571136

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2025/014711

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 1020267000338

Country of ref document: KR

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A15-NAP-PA0105 (AS PROVIDED BY THE NATIONAL OFFICE)

WWE Wipo information: entry into national phase

Ref document number: 1020267000338

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2024820201

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2024820201

Country of ref document: EP

Effective date: 20260107

ENP Entry into the national phase

Ref document number: 2024820201

Country of ref document: EP

Effective date: 20260107

ENP Entry into the national phase

Ref document number: 2024820201

Country of ref document: EP

Effective date: 20260107

ENP Entry into the national phase

Ref document number: 2024820201

Country of ref document: EP

Effective date: 20260107

ENP Entry into the national phase

Ref document number: 2024820201

Country of ref document: EP

Effective date: 20260107

WWP Wipo information: published in national office

Ref document number: 1020267000338

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2024820201

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: MX/A/2025/014711

Country of ref document: MX